Elevation of CXCL1 indicates poor prognosis and radioresistance by inducing mesenchymal transition in glioblastoma

Elevation of CXCL1 indicates poor prognosis and radioresistance by inducing mesenchymal transition in glioblastoma

Introduction Glioblastoma (GBM) is identified as a lethal malignant tumor derived from the nervous system. Despite the standard clinical strategy including maximum surgical resection, temozolomide (TMZ) chemotherapy, and radiotherapy, the median survival of GBM patients remains

Gespeichert in:
Bibliographische Detailangaben
Veröffentlicht in:CNS neuroscience & therapeutics 2020-04, Vol.26 (4), p.475-485
Hauptverfasser: Alafate, Wahafu, Li, Xiaodong, Zuo, Jie, Zhang, Hua, Xiang, Jianyang, Wu, Wei, Xie, Wanfu, Bai, Xiaobin, Wang, Maode, Wang, Jia
Format: Artikel
Sprache:eng
Schlagworte:
Apoptosis
Brain cancer
Cell proliferation
Chemokines
Chemotherapy
CXCL1
epithelial‐mesenchymal transition
Flow cytometry
Gastric cancer
Gene expression
Glioblastoma
Immunoglobulins
Medical prognosis
Mesenchyme
Nervous system
NF‐κB
Ontology
Original
Prognosis
Radiation therapy
Radioresistance
Software
Statistical analysis
Survival analysis
Temozolomide
Therapeutic applications
Online-Zugang:Volltext
Tags: Tag hinzufügen
Keine Tags, Fügen Sie den ersten Tag hinzu!
Beschreibung
Zusammenfassung:Introduction Glioblastoma (GBM) is identified as a lethal malignant tumor derived from the nervous system. Despite the standard clinical strategy including maximum surgical resection, temozolomide (TMZ) chemotherapy, and radiotherapy, the median survival of GBM patients remains
ISSN:1755-5930
1755-5949
DOI:10.1111/cns.13297